FiercePharmaPolitics—House passes Pelosi bill, Trump admin nixes biologics protections in trade pact and more

Drug prices
The House of Representatives passed speaker Nancy Pelosi's drug pricing bill in a mostly party-line vote last week. (Getty/Tero Vesalainen)

Welcome to the FiercePharma political roundup, where each Monday we’ll highlight notable developments that could affect how drugmakers operate. 

As the year comes to an end, lawmakers and government officials made a few moves on the drug pricing front last week. The House passed speaker Nancy Pelosi’s drug pricing plan, and Trump administration officials agreed to terms on the USMCA trade pact, plus more.

On the Pelosi plan, lawmakers passed the bill Thursday in a mostly party-line vote. Still, experts don’t believe it’ll gain any more momentum as the Senate is unlikely to take up the bill for a vote. Further, President Donald Trump has said he’ll veto it if it reaches his desk. Still, with its passing in the House, Democrats will be able to say on the campaign trail next year that they tried to fight high drug prices. 

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

The plan calls for Medicare price negotiations, an international price index, fines for those drugmakers who don't negotiate and more. Activist billionaires John and Laura Arnold have spent tens of millions of dollars supporting Pelosi's bill and others, Stat recently highlighted. And former FDA commissioner Scott Gottlieb wrote a Wall Street Journal op-ed detailing how the plan would curtail innovation, following an industry line of attack against the bill. 

Alternatively, in the Senate, lawmakers are working on other options that aren’t as aggressive as Pelosi’s pricing plan. Cowen analysts wrote last week that it doesn’t appear those options will get a floor vote this year. 

RELATED: Trump admin moves to scrap biologics exclusivity in trade deal—and pharma's not amused 

Outside of those developments, the Trump administration agreed to scrap biologics exclusivity in trade negotiations with Canada and Mexico last week, angering pharma. With the move, the countries can individually set their biologics exclusivity rules.  

The decision “declares open season” on innovative pharma companies and “sends a clear message that the U.S. government will stand idly by while foreign entities attack American intellectual property, American jobs and America’s global leadership in medical innovation," Jim Greenwood, head of industry group BIO, said in a statement.

RELATED: It's official: New FDA Commissioner Hahn wins Senate confirmation

Lastly, the Senate confirmed new FDA commissioner Stephen Hahn last week. Hahn is “very interested” in the ways the FDA can stimulate competition and lower costs, he said during a confirmation hearing.

Read more on

Suggested Articles

Pfizer and Merck KGaA’s Bavencio is heading toward a piece of the crowded bladder cancer market that it can call its own.

IDEA Pharma ranks AstraZeneca at the top of the pharma invention scale, and Roche became king in the land of innovation.

Will Pfizer's Braftovi-Erbitux combo in BRAF-mutated colon cancer be the standard of care? Adding Mektovi may be the real opportunity, some predict.